Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Trial ID or NCT#

NCT06465810

Status

recruiting iconRECRUITING

Purpose

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Official Title

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

Eligibility Criteria

Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. * Patient willing and able to provide written informed consent to participate in the study* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis* Aged ≥18 years at the time of signing the informed consent* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
Exclusion Criteria:
  1. * Concurrent participation in any interventional trial for ATTR amyloidosis* Involvement in the planning and/or conduct of the current study* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers
View All Criteria
Show Less

Investigator(s)

Kevin M. Alexander, MD, FACC, FHFSA
Kevin M. Alexander, MD, FACC, FHFSA
Heart failure cardiologist
Assistant Professor of Medicine (Cardiovascular Medicine)

Contact us to find out if this trial is right for you.

Contact

AstraZeneca Clinical Study Information Center
1-877-240-9479

SEND MESSAGE

View on ClinicalTrials.gov